Dr. Stephan, the founder, president and CEO of SV Bio, is a geneticist, entrepreneur and recognized leader in the field of personalized medicine. Prior to SV Bio, he was Executive Director of the Gene Partnership at Harvard Medical School and Children's Hospital Boston, where he architected and capitalized a groundbreaking genomic medicine pediatric program, as well as a genomic cancer program at Fox Chase Cancer Center. Dr. Stephan brought next-generation genome sequencing (NGS) to these clinical settings, with associated clinical decision support and sustainable business processes. In 2006, Dr. Stephan founded Navigenics, Inc., a pioneering consumer genomics company, and later served as the company's Chief Science Officer. Prior to that, he served as part of the leadership team of the Translational Genomics Research Institute (TGen), building it into one of the largest free-standing research institutes in the world. His roles at the Institute were Chairman of the Neurogenomics Department, Professor within the Institute, and Deputy Director for Discovery Research of the Institute overall. Dr. Stephan also served as Chairman of the NIH Neuroscience Microarray Consortium for seven years. Dr. Stephan has published over 140 articles in peer-reviewed scientific journals, and he is a member of the Scientific Advisory Boards of many companies. He is on the Board of Directors of several organizations, including the Personalized Medicine Coalition, and continues to found biotechnology companies, including Aueon, Amnestix, and DiaVacs. Among numerous honors and awards, Dr. Stephan has won the Bio-IT World Grand Prize for Discovery Research in 2005, and the "Most Influential in Bringing Genomics to the Clinic" award at the Consumer Genetic Conference in 2010. Dr. Stephan earned a B.Sc. in biology from Carnegie Mellon University and a Ph.D. in Human Genetics from the University of Pittsburgh Graduate School of Public Health, where he was a 2012 "Legacy Laureate".